Featured news from NHIVNA

HIV-related news from NAM

Simeprevir with interferon effective for HIV/HCV co-infected people with genotype 1 hepatitis C
Liz Highleyman, 2013-10-21 08:50:00

Adding the direct-acting hepatitis C drug simeprevir to pegylated interferon and ribavirin produced high response rates for HIV-positive people co-infected with HCV genotype 1, researchers reported at the 14th European AIDS Conference this week in Brussels. Particularly impressive was a 57% sustained response rate for prior null responders. Another study showed simeprevir to be active against HCV genotype 4 in mono-infected patients.

The advent of direct-acting antivirals has brought about a new era of treatment for hepatitis C. These drugs will ultimately be used in all-oral regimens but those approved first will initially be used as add-ons to standard therapy with pegylated interferon/ribavirin.